Top GLP-1

GLP-1 glossary

TGBy the Top GLP-1 Editorial Team· Reviewed 2026-09-01· Cites FDA & NEJM· Not medical advice
Plain-language definitionsHow we rank →

Every GLP-1 term you'll run into — the medications, the mechanisms, the pharmacy and insurance jargon — defined in one clear sentence.

GLP-1 (glucagon-like peptide-1)
A hormone the gut releases after eating that curbs appetite, slows stomach emptying and helps regulate blood sugar. GLP-1 medications are long-acting mimics of it.Learn more
GLP-1 receptor agonist
A drug that activates the GLP-1 receptor to reduce appetite and improve blood-sugar control — the mechanism behind semaglutide and other weight-loss medications.
GIP (glucose-dependent insulinotropic polypeptide)
A second gut hormone involved in appetite and metabolism. Tirzepatide activates both GIP and GLP-1 receptors, which is thought to add to its effect.
Semaglutide
The GLP-1 medication sold as Wegovy (weight loss), Ozempic (diabetes) and Rybelsus (oral diabetes). Averaged about 15% weight loss in trials.Learn more
Tirzepatide
A dual GIP/GLP-1 medication sold as Zepbound (weight loss) and Mounjaro (diabetes). Produced the most average weight loss of the approved options (up to ~21%).Learn more
Retatrutide
An investigational 'triple agonist' (GIP/GLP-1/glucagon) that showed the highest weight loss in early trials (~24%) but is not FDA-approved and not legally available.Learn more
Liraglutide
An older, once-daily GLP-1 sold as Saxenda (weight loss) and Victoza (diabetes). Less weight loss than the weekly drugs (~8%), now available as a generic in some markets.Learn more
Compounded medication
A drug prepared by a compounding pharmacy rather than a branded, FDA-approved finished product. Compounded GLP-1 is the same active molecule at far lower cost, but isn't individually FDA-reviewed.Learn more
503A pharmacy
A state-licensed compounding pharmacy that prepares patient-specific prescriptions. Reputable telehealth GLP-1 programs use licensed 503A (or 503B) pharmacies.
LegitScript certification
A third-party certification indicating a legitimate, compliant online pharmacy or telehealth operation — a useful trust signal when choosing a compounded GLP-1 program.Learn more
Dose titration (escalation)
Gradually increasing the dose over several weeks so the body adapts. Rushing titration is the main cause of severe nausea on GLP-1 medications.Learn more
Maintenance dose
The target dose reached after titration (for example, 2.4 mg weekly for Wegovy). Not everyone needs the maximum dose to reach their goal.
BMI (body mass index)
A weight-to-height ratio used as a screening threshold. GLP-1 weight-loss drugs are generally indicated at a BMI of 30+, or 27+ with a weight-related condition.Learn more
Prior authorization
An insurer's requirement to approve coverage before it will pay for a medication. It's common for GLP-1 drugs, even when a plan covers them.Learn more
Off-label
Prescribing an FDA-approved drug for a use not listed on its label — for example, using Ozempic (approved for diabetes) for weight loss.
Dual / triple agonist
A drug that activates two receptors (dual, like tirzepatide's GIP + GLP-1) or three (triple, like retatrutide's GIP + GLP-1 + glucagon).
Subcutaneous injection
An injection into the fat layer just under the skin — how most GLP-1 medications are given, usually once weekly with a small needle.
MACE (major adverse cardiovascular events)
Heart attack, stroke or cardiovascular death. Semaglutide reduced MACE by 20% in the SELECT trial for adults with obesity and heart disease.
Food noise
The intrusive, persistent thoughts about food many people describe — which GLP-1 medications often quiet, making it easier to eat less.
Oral GLP-1
A pill form of a GLP-1 drug, such as Rybelsus (oral semaglutide). Effective, but the most powerful GLP-1 treatments are still weekly injections.
"Ozempic face"
A deflated or gaunt facial appearance that can follow rapid weight loss. It's a result of fast fat loss from any cause, not a unique drug side effect.
GLP-1 Bridge (Medicare)
A temporary Medicare demonstration (July 2026–December 2027) offering Wegovy, Zepbound or Foundayo for a $50 copay to eligible Part D members, outside the standard benefit.Learn more

New to GLP-1? Start with how GLP-1 works or the quick answers.